Clinical Trials Logo
  1. Home
  2. Melasma
  3. NCT03826277

Efficacy of Melanostop Peeling for Improvement of Melasma — VIMEL  

Melasma Clinical Trial

Official title:
The Efficacy of Melanostop Peel in Combination With Specifically Selected Home Care Regimen for Improvement of Melasma

Clinical Trial Summary

Participants with face melasma will receive 4 Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol and 6% phytic acid. Peels will be performed at 2-week interval. They will also receive a facial tonic and cream for at home use, containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid. They will also receive sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR. Products for at home use will be used twice a day, every day. Measurements will be made at baseline, on the day of the forth peel treatment and 4 weeks after the last peel. Measured parameters will be: mMASI score, VisioFace photography analysis, melasma area measurements, and melanin index, ΔE, CIELab colour measurements with Cortex SkinLab Combo (Cortex Technology Asp, Denmark).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03826277
Study type Interventional
Source VIST - Faculty of Applied Sciences
Contact
Status Active, not recruiting
Phase N/A
Start date February 1, 2019
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma N/A
Recruiting NCT06174545 - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma N/A
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Recruiting NCT06278948 - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma N/A
Not yet recruiting NCT05911698 - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. N/A
Recruiting NCT05656833 - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma N/A
Recruiting NCT04597203 - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Terminated NCT03415685 - Lutronic PicoPlus Exploratory Clinical Trial N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Completed NCT04137263 - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging N/A
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT05969587 - Cysteamine Compared to Hydroquinone in Melasma Phase 3
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT05884151 - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Phase 1
Completed NCT05887219 - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Phase 1
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3